PREDICT-RD: ctDNA Surveillance in TNBC with Residual Disease

This research study aims to investigate the use of circulating tumor DNA (ctDNA) monitoring to detect early signs of cancer recurrence in patients with triple-negative breast cancer (TNBC) after standard treatment. TNBC is aggressive and has a higher risk of recurrence, often detected only after symptoms appear. This study will monitor ctDNA levels through blood samples collected during and after adjuvant therapy. If ctDNA is not detected, participants will continue monitoring. If ctDNA is detected, the study offers an investigational treatment, datopotamab deruxtecan (Dato-DXd), to address this potential recurrence risk. Participation in this study will help determine if ctDNA monitoring can improve the early detection of recurrence and potentially lead to better treatment strategies and outcomes for patients with TNBC in the future.